Reply to Wegovy with insur coverage vs Zepbound self-pay

Forum Index » Diet, Nutrition & Weight Loss

Reply to "Wegovy with insur coverage vs Zepbound self-pay"

Subject:

Emoticons





More smilies

Text Color: Font: Close Marks

[quote=Anonymous]Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA-approved prescription medications used for chronic weight management in adults who are obese or overweight with at least one weight-related health condition. They are both administered as once-weekly subcutaneous injections. 
Here's a comparison of Zepbound and Wegovy:
Mechanism of Action:
Zepbound: Zepbound is a dual-agonist drug, meaning it activates receptors for both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These are natural hormones that help regulate appetite, blood sugar levels, and digestion. By activating these receptors, Zepbound can slow down how quickly food moves through the digestive tract, make you feel full for longer, and potentially lower blood sugar levels. This dual action contributes to appetite suppression and food intake reduction.
Wegovy: Wegovy is a single-agonist drug, primarily activating GLP-1 receptors in the brain. GLP-1 mimics the natural hormone to reduce appetite, slow gastric emptying, and promote feelings of fullness. 
Effectiveness:
Clinical trials suggest that Zepbound may lead to more significant weight loss than Wegovy.
In one study, patients on Zepbound lost an average of 20.2% of their body weight (approximately 50.3 pounds) after 72 weeks, while those on Wegovy lost an average of 13.7% (approximately 33.1 pounds).
Zepbound also led to a greater reduction in waist circumference (an average of 7.2 inches) compared to Wegovy (an average of 5.1 inches). [/quote]

Options

	Disable HTML in this message
	Disable BB Code in this message
	Disable smilies in this message

Review message

Search Recent Topics Hottest Topics